New Inhibrx results for Ewing sarcoma drug could not be verified ahead of Seoul presentation
Key Facts
New clinical results for ozekibart, which Inhibrx Biosciences is developing to treat Ewing sarcoma, could not be verified ahead of their scheduled presentation in Seoul on November 19 and 20, 2026. The company said in its disclosure that updated data would be presented at the annual meeting of the Connective Tissue Oncology Society. The trial is evaluating the drug with irinotecan and temozolomide in patients with treatment-resistant Ewing sarcoma. The presentation date remains a future event relative to the date of the news, not a presentation that had already been announced. The company describes the drug as experimental, while the Phase 1 trial continues to enroll patients in combination-treatment cohorts.
The company's earlier results provide a separate point of comparison from the data expected to be presented in Seoul. Inhibrx reported that 31 patients were evaluable for response as of January 15, 2026, and that this group had an objective response rate of 64.5% and a disease control rate of 87.1%. The rates are tied to the stated cutoff date and do not represent the new update that could not be verified. In an update presented in March 2026, the company said responses were ongoing in 8 patients. One of them had been on treatment for more than two years without disease progression, according to its disclosure.
The study is being conducted as a single-arm Phase 1/2 trial, according to the company's presentation filed with the U.S. Securities and Exchange Commission. The treatment regimen lists an ozekibart dose of 3 mg/kg, with irinotecan at 50 mg/m² daily and temozolomide at 100 mg/m² daily. The age criteria shown include patients aged 12 years to under 85 years. The presentation also cited reference response rates ranging from 15% to 30% for irinotecan with temozolomide, and from 20% to 25% for high-dose ifosfamide. These are reference figures cited by the company, not a direct randomized comparison between treatments in the study.
On safety, the company said the most common side effects in the Ewing sarcoma data were diarrhea, nausea, anemia and fatigue. It added that these effects were consistent with the known safety profile of the two chemotherapy agents used in the combination. The presentation did not provide counts or rates for these effects in the available information. Phase 1 continues to enroll patients in combination-treatment cohorts for Ewing sarcoma, alongside colorectal cancer cohorts, according to the company's website. This places ozekibart in an ongoing clinical program, without changing its description as an experimental treatment.
Inhibrx plans to complete patient enrollment in the Ewing sarcoma trial during 2027, according to its third-quarter 2026 report. It also said the study's patient cohort was expanded to accommodate up to 50 additional patients following the preliminary data. On regulatory steps, the company is considering submitting the clinical data to the National Comprehensive Cancer Network for consideration of ozekibart as a potential treatment option in its Ewing sarcoma guidelines. The company did not disclose a decision on inclusion in the available disclosure. The Seoul presentation comes ahead of the enrollment completion date the company expects in 2027.